Blood-Retinal Barrier
Anatomy, Physiology, Pathophysiology & Clinical Applications
Examination question · ~800 words
What is the blood-retinal barrier? Discuss its anatomical components (inner and outer BRB), mechanisms of transport, regulation of barrier integrity, pathophysiological breakdown in major retinal diseases, diagnostic assessment, and management strategies targeting BRB restoration.
Try to outline your answer mentally before expanding sections below.
The blood-retinal barrier (BRB) is a specialised neurovascular structure that maintains the unique microenvironment of the retina by regulating the passage of molecules, ions, and cells between the systemic circulation and retinal tissue. Analogous to the blood-brain barrier, it comprises two anatomically distinct components — the inner BRB (iBRB) and outer BRB (oBRB) — and its breakdown is the final common pathway underlying virtually all major sight-threatening retinal diseases. Understanding the mechanisms of BRB dysfunction and target-directed therapeutic strategies is essential for postgraduate ophthalmic practice.
A. Inner BRB (iBRB)
- Formed by tight junctions (_zonulae occludentes_) between retinal capillary endothelial cells
- Key tight junction proteins: Claudin-5, Occludin, ZO-1, ZO-2, JAM-A
- Supported by pericytes, Müller cells, astrocytes, and microglia — collectively forming the Neurovascular Unit (NVU)
- Pericytes maintain endothelial junction integrity via PDGF-B / PDGFRβ signalling
- Müller cell end-feet ensheath retinal capillaries; secrete barrier-maintaining factors (GDNF)
B. Outer BRB (oBRB)
- Formed by tight junctions between RPE cells — sitting on Bruch's membrane with fenestrated choriocapillaris on its outer side
- Tight junction proteins: Claudin-1, Claudin-3, Occludin, ZO-1
- RPE expresses polarised transporters (apical vs basolateral) for glucose (GLUT1), ions, and fluid
- Choriocapillaris is fenestrated — the RPE layer itself constitutes the outer barrier
| Feature | iBRB | oBRB |
|---|---|---|
| Location | Retinal capillary endothelium | RPE tight junctions |
| Adjacent structure | Pericytes, Müller cells, astrocytes | Bruch's membrane, choriocapillaris |
| Fluid when disrupted | Intraretinal fluid (IRF) | Subretinal fluid (SRF) |
| Key tight junction proteins | Claudin-5, Occludin, ZO-1 | Claudin-1/3, Occludin |
| Key disease associations | DR, RVO, uveitis | AMD, CSCR, VKH |
| Main disruptor | VEGF, PKC-β, inflammation | VEGF, oxidative stress, RPE ageing |
| Mechanism | Details / Example |
|---|---|
| Paracellular (restricted) | Blocked by tight junctions under normal conditions |
| Transcellular passive diffusion | Lipid-soluble molecules, O₂, CO₂ |
| Carrier-mediated transport | Glucose via GLUT1; amino acids via specific carriers |
| Active transport | Na⁺/K⁺ ATPase at RPE — drives vectorial fluid transport |
| Receptor-mediated endocytosis | LDL, transferrin |
| Efflux pumps | P-glycoprotein — limits drug penetration into retina |
A. VEGF — Key Disruptor
- Most potent BRB permeabilising factor
- Binds VEGFR-2 → activates PKC and Src kinase → phosphorylates Occludin / Claudin-5 → tight junction disassembly
- Also promotes endothelial fenestration and leukostasis (capillary plugging → ischaemia)
B. Angiopoietin-1 / Ang-2 Axis
- Ang-1 (pericyte-derived): activates Tie-2 receptor → stabilises junctions via Akt/PI3K → barrier-protective
- Ang-2 (stored in Weibel-Palade bodies): competitively antagonises Ang-1 at Tie-2 → destabilises junctions, sensitises to VEGF → barrier-disruptive
C. Other Disruptors
- TNF-α, IL-1β, IL-6 — inflammatory cytokines (uveitis, RVO)
- Advanced glycation end-products (AGEs) — diabetes
- Oxidative stress → HIF-1α upregulation → VEGF transcription
- PKC-β activation — key early pathway in diabetic BRB breakdown
Types of Breakdown
| Type | Mechanism | Clinical Example |
|---|---|---|
| Vasogenic | Tight junction disruption → paracellular leak [iBRB] | DR, CRVO |
| Cytotoxic | Cellular swelling — intracellular oedema | Ischaemia, blunt trauma |
Disease-Specific Mechanisms
- Diabetic Retinopathy: Hyperglycaemia → AGEs + PKC-β activation + polyol pathway → selective pericyte loss → endothelial vulnerability → VEGF → iBRB breakdown → DME; leukostasis contributes to capillary non-perfusion
- AMD: RPE dysfunction + Bruch's thickening → oBRB failure; VEGF from RPE/Müller cells drives CNV; Type 2/3 neovascularisation disrupts oBRB → SRF
- CSCR: Choroidal hyperpermeability overwhelms RPE active pumping → focal oBRB failure → SRF accumulation
- RVO: Venous stasis → ischaemia → HIF-1α → VEGF → iBRB breakdown → macular oedema (vasogenic + cytotoxic components)
- Uveitis: Inflammatory cytokines (TNF-α, IL-6) disrupt iBRB and oBRB; cystoid macular oedema via prostaglandin-mediated leakage
- Macular oedema — most vision-threatening outcome (IRF, SRF, sub-RPE fluid)
- Hard exudates — chronic lipoprotein extravasation and deposition in outer plexiform layer
- Neovascularisation — ischaemia-driven VEGF upregulation (PDR, CNV in AMD)
- Disc oedema — in posterior uveitis / VKH via uvea-derived cytokine-mediated BRB disruption
- Photoreceptor loss — chronic fluid disrupts IS/OS junction integrity (OCT hallmark)
| Investigation | Assesses | Key Points |
|---|---|---|
| FFA | iBRB leakage (gold standard) | Leakage pattern: pooling / staining / petalloid; maps non-perfusion; RPE window defects (hyperfluorescence through atrophic RPE → unmasked choroidal background) |
| ICG Angiography | oBRB / choroidal circulation | Polypoidal lesions (PCV gold standard); choroidal hyperpermeability hotspots (CSCR); CNV delineation |
| SD-OCT / SS-OCT | Fluid compartments | IRF vs SRF vs sub-RPE; IS/OS integrity; CMT quantification |
| OCTA | Capillary non-perfusion; FAZ | Non-invasive; no leakage info; complements FFA |
| Vitreous fluorophotometry | Quantitative BRB permeability | Research tool; not routine clinical practice |
| Microperimetry | Functional correlation | Maps scotoma over areas of BRB disruption |
A. Anti-VEGF Therapy — Cornerstone
| Agent | Mechanism | Key Trial / Indication |
|---|---|---|
| Ranibizumab | Anti-VEGF-A Fab fragment | MARINA/ANCHOR (AMD); RIDE/RISE (DME) |
| Bevacizumab | Full IgG anti-VEGF-A (off-label) | CATT trial (AMD) — non-inferior to ranibizumab |
| Aflibercept 2 mg | VEGF-A/B + PlGF trap | VIEW 1/2 (AMD); VISTA/VIVID (DME) |
| Aflibercept 8 mg | High-dose; extended dosing | PHOTON (DME); PULSAR (AMD) — Q16 intervals |
| Brolucizumab | Anti-VEGF-A scFv; 6 mg | HAWK/HARRIER (AMD) — Q12 durability |
| Faricimab | Dual Ang-2 + VEGF-A inhibitor | YOSEMITE/RHINE (DME); TENAYA/LUCERNE (AMD) |
B. Corticosteroids
- Inhibit VEGF transcription + stabilise tight junctions + reduce inflammatory cytokines
- Intravitreal triamcinolone — short-term; cataract / IOP risks
- Dexamethasone implant (Ozurdex) — biodegradable; 3–6 months; RVO-related CMO preferred
- Fluocinolone implant (Iluvien) — 36-month sustained release; chronic diabetic CMO
- Preferred when uveitic aetiology or anti-VEGF non-responder; steroid-naïve IOP check essential
C. Laser Photocoagulation
- Focal/grid laser for DME — reduces VEGF from hypoxic zones; stimulates RPE pump function
- ETDRS landmark trial — established laser benefit in clinically significant macular oedema (CSME)
- Now second-line to anti-VEGF; still relevant for extrafoveal CSME
D. Photodynamic Therapy (PDT)
- Verteporfin PDT in CSCR — reduces choroidal hyperpermeability; restores oBRB function
- Half-dose / half-fluence PDT preferred to minimise RPE toxicity (PLACE trial evidence)
E. Carbonic Anhydrase Inhibitors
- Oral acetazolamide — enhances RPE fluid pumping via CA-dependent ion transport mechanism
- Used in chronic CSCR; also topical CAIs trialled with modest effect
Faricimab targets both VEGF-A and Angiopoietin-2. Mechanistically, why does Ang-2 blockade confer additional benefit over VEGF-A inhibition alone in stabilising the BRB, and what is the rationale for combining these targets within the neurovascular unit framework?
Answer
VEGF-A inhibition prevents acute permeability by blocking tight junction phosphorylation (Occludin/Claudin-5 via Src kinase), but does not address chronic vascular destabilisation mediated by Ang-2. Ang-2, released from Weibel-Palade bodies under hypoxic or inflammatory stress, competitively antagonises Ang-1 at the Tie-2 receptor on endothelial cells, reducing pericyte-endothelium crosstalk and priming the vasculature to VEGF-mediated leakage. In the diseased NVU, pericyte dropout (as in DR) renders endothelial cells more dependent on Ang-1/Tie-2 signalling for barrier maintenance. Ang-2 blockade by faricimab restores effective Ang-1/Tie-2 activation → intracellular Akt/PI3K signalling → tight junction stabilisation and pericyte recruitment. This dual mechanism addresses both the acute (VEGF) and chronic structural (Ang-2) components of BRB failure — explaining the superior fluid resolution and extended treatment intervals (Q16 in YOSEMITE/RHINE) observed versus anti-VEGF monotherapy.
References
- Yanoff M, Duker JS. Ophthalmology. Elsevier. 5th ed.
- Kanski JJ, Bowling B. Clinical Ophthalmology: A Systematic Approach. Elsevier. 8th ed.
- Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. pp 1227–1239
- Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. pp 67–81
- Wykoff CC et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks (YOSEMITE/RHINE). Lancet. pp 741–755
- Heier JS et al. Intravitreal aflibercept 8mg in neovascular AMD (PULSAR). Ophthalmology. pp 686–696
- ETDRS Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. pp 1796–1806
- Daruich A et al. Mechanisms of macular edema — beyond the surface. Prog Retin Eye Res. pp 20–68
- Cunha-Vaz JG. The blood-ocular barriers: past, present and future. Doc Ophthalmol. pp 149–157
- Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. pp 261–270